UPDATED: US FDA Has People Working At CMS To Help Implement Inflation Reduction Act
Executive Summary
The FDA was mum on the expertise that it appears to be lending the payer, but Commissioner Robert Califf reiterated that communication between the agency and CMS is increasing.
You may also be interested in...
FDA’s Califf Speaks Of Tailoring Trials For CMS Evidence Amid Spotlight On Alzheimer’s Drugs
FDA Commissioner Robert Califf spoke of the need for a better hand-off to CMS, including tailoring trials to generate evidence relevant for Medicare coverage. He also weighed in on the possibility of accelerated approval for chronic disease drugs, among other topics.
US FDA Set To Begin Training Patent Examiners This Spring
Prompted by an Executive Order on drug price competition, the cross-agency training aims to ensure that the Patent and Trademark Office is aware of all information that FDA makes available.
Eisai’s Leqembi Launch Bodes Well For Biogen In A Pivotal Year
Eisai said the US launch of Alzheimer’s therapy Leqembi following accelerated approval is going well, which is welcome news for partner Biogen as it brings on a new CEO and recovers from a failed Aduhelm launch.